{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:26:57Z","timestamp":1789712817059,"version":"4.0.1"},"reference-count":48,"publisher":"CMA Joule Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAJ Open"],"published-print":{"date-parts":[[2017,2,3]]},"DOI":"10.9778\/cmajo.20160161","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T01:50:13Z","timestamp":1486173013000},"page":"E97-E108","source":"Crossref","is-referenced-by-count":20,"title":["Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis"],"prefix":"10.9778","volume":"5","author":[{"given":"William W. L.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"382","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"key":"2017020317500824000_5.1.E97.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"2017020317500824000_5.1.E97.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"2017020317500824000_5.1.E97.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"2017020317500824000_5.1.E97.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"2017020317500824000_5.1.E97.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"2017020317500824000_5.1.E97.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"2017020317500824000_5.1.E97.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"2017020317500824000_5.1.E97.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"2017020317500824000_5.1.E97.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"2017020317500824000_5.1.E97.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"2017020317500824000_5.1.E97.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"2017020317500824000_5.1.E97.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"2017020317500824000_5.1.E97.13","unstructured":"Murphy G, Farah B, Wong WWL, et al. CADTH THERAPEUTIC REVIEW 7: Scientific report: direct acting antiviral agents for chronic hepatitis C Genotype 1. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2014"},{"key":"2017020317500824000_5.1.E97.14","unstructured":"TreeAge 2014 Professional. Williamstown (MA): TreeAge Software; 2014."},{"key":"2017020317500824000_5.1.E97.15","unstructured":"Therapeutic review: drugs for chronic hepatitis C infection [clinical report]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015."},{"key":"2017020317500824000_5.1.E97.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02748.x"},{"key":"2017020317500824000_5.1.E97.17","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.083113"},{"key":"2017020317500824000_5.1.E97.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"2017020317500824000_5.1.E97.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01481.x"},{"key":"2017020317500824000_5.1.E97.20","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X03261568"},{"key":"2017020317500824000_5.1.E97.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7753"},{"key":"2017020317500824000_5.1.E97.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"2017020317500824000_5.1.E97.23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280333"},{"key":"2017020317500824000_5.1.E97.24","unstructured":"Therapeutic review: drugs for chronic hepatitis C infection [pharmacoeconomic report]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015."},{"key":"2017020317500824000_5.1.E97.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-6640-4"},{"key":"2017020317500824000_5.1.E97.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06813.x"},{"key":"2017020317500824000_5.1.E97.27","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315240"},{"key":"2017020317500824000_5.1.E97.28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21409"},{"key":"2017020317500824000_5.1.E97.29","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06290495"},{"key":"2017020317500824000_5.1.E97.30","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/569692"},{"key":"2017020317500824000_5.1.E97.31","first-page":"425","article-title":"Factors associated with the high cost of liver transplantation in adults.","volume":"45","author":"Taylor","year":"2002","journal-title":"Can J Surg"},{"key":"2017020317500824000_5.1.E97.32","doi-asserted-by":"publisher","DOI":"10.1586\/erp.12.10"},{"key":"2017020317500824000_5.1.E97.33","unstructured":"Table 3260021: Consumer Price Index (CPI) - annual (2002=100) [2005 basket]. Ottawa: Statistics Canada; 2015. Availablewww5.statcan.gc.ca\/cansim\/a26?id=3260021 . accessed 2017 Jan. 9."},{"key":"2017020317500824000_5.1.E97.34","unstructured":"Guidelines for the economic evaluation of health Technologies. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006. Availablewww.cadth.ca\/media\/pdf\/186_EconomicGuidelines_e.pdf accessed 2016 June 1 ."},{"key":"2017020317500824000_5.1.E97.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.2.228"},{"key":"2017020317500824000_5.1.E97.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.24.2088"},{"key":"2017020317500824000_5.1.E97.37","first-page":"473","article-title":"How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.","volume":"146","author":"Laupacis","year":"1992","journal-title":"CMAJ"},{"key":"2017020317500824000_5.1.E97.38","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"key":"2017020317500824000_5.1.E97.39","unstructured":"Choosing interventions that are cost effective (WHO-CHOICE). Geneva: World Health Organization; 2005"},{"key":"2017020317500824000_5.1.E97.40","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307772"},{"key":"2017020317500824000_5.1.E97.41","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"},{"key":"2017020317500824000_5.1.E97.42","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1152"},{"key":"2017020317500824000_5.1.E97.43","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0320-4"},{"key":"2017020317500824000_5.1.E97.44","doi-asserted-by":"crossref","unstructured":"Foster GR, Pianko S, Cooper C, et al. Sofosbuvir plus Peg-IFN\/RBV for 12 weeks vs Sofosbuvir\/RBV for 16 or 24 weeks in Genotype 3 HCV-Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study. Proceedings of EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver; 2015 Apr. 22-26","DOI":"10.1016\/S0168-8278(15)30151-3"},{"key":"2017020317500824000_5.1.E97.45","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1313"},{"key":"2017020317500824000_5.1.E97.46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3111\/13696998.2015.1106546","article-title":"Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.","volume":"19","author":"Moshyk","year":"2016","journal-title":"J Med Econ"},{"key":"2017020317500824000_5.1.E97.47","unstructured":"Drugs for chronic hepatitis C infection: recommendations report. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015."},{"key":"2017020317500824000_5.1.E97.48","unstructured":"Rotermann M, Langlois K, Andonov A, et al. Health Reports: Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Ottawa: Statistics Canada; 2013. Cat. no. 82-003-X"}],"container-title":["CMAJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.9778\/cmajo.20160161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T07:34:15Z","timestamp":1568792055000},"score":1,"resource":{"primary":{"URL":"http:\/\/cmajopen.ca\/lookup\/doi\/10.9778\/cmajo.20160161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,3]]},"published-print":{"date-parts":[[2017,2,3]]}},"alternative-id":["10.9778\/cmajo.20160161"],"URL":"https:\/\/doi.org\/10.9778\/cmajo.20160161","relation":{},"ISSN":["2291-0026"],"issn-type":[{"value":"2291-0026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,3]]}}}